araag2/HINT huggingface dataset:
Clinical trial NCT00254618 (phase 1, status: terminated)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mesalamine, mesalamine, mesalamine
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1
Reason stopped: 
    slow enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

        Patients are eligible to participate in the study if they have/are:

          1. male or female between the ages of 5 and 17 years, inclusive, at the time of the first
             dose of study medication

          2. mildly to moderately active ulcerative colitis (either newly- or
             previously-diagnosed), as confirmed by their physician, for which mesalamine would be
             used as part of their normal treatment

          3. generally in good health (other than the diagnosis of ulcerative colitis), based on
             medical history, physical examination, and screening laboratory results

          4. able to swallow Asacol tablets (400 mg marketed US formulation)

          5. a body weight no less than 16 kg and no more than 90 kg

          6. able and willing to participate in the study and follow study procedures, as evidenced
             by providing assent and having a parent/guardian-signed written informed consent.

        Exclusion Criteria:

        Patients will be excluded from the study if they have/are:

        1. a history of cancer 2. a history of intestinal surgery or malabsorption 3. a history of
        renal insufficiency 4 a history of allergy or hypersensitivity to salicylates or
        aminosalicylates 5. evidence of clinically significant organic or psychiatric disease on
        medical history or physical examination that, in the Investigator's opinion, would prevent
        the patient from completing the study or would jeopardize the patient's safety 6. a
        creatinine clearance of < or =30 mL/minute at screening, estimated by serum creatinine
        using the Traub & Johnson equation for calculating pediatric creatinine clearance.

        7. a screening BUN or creatinine value that is >1.5 times the upper limit of normal, or
        liver function tests that are >2 times the upper limit of normal 8. any other screening
        laboratory test values that the Investigator or Sponsor considers clinically significant
        that would impact the outcome of the study or the safety of the patient 9. using proton
        pump inhibitors or antacids 10. pregnant (post-menarchal female patients should be made
        aware that pregnancy testing will occur during the study, and that if they are sexually
        active they must take appropriate steps to ensure they do not become pregnant during the
        study) 11. a positive urine screen for drugs of abuse 12. participated in another clinical
        trial involving active intervention within 30 days prior to randomization.
Clinical trial NCT01433731 (phase 1, status: completed)
Conditions: lymphoma, t-cell, cutaneous
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: placebo for shape (shp-141), shape (shp-141) 0.1% bid, shape (shp-141) 0.5% bid, shape (shp-141) 1.0% bid
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologically confirmed CTCL; a documented verifiable biopsy report is required.

          -  Documented clinical Stage IA, IB, or IIA CTCL.

          -  Skin lesion involvement of at least 3% of BSA accessible for topical application of
             study drug and biopsy.

          -  ECOG performance status of 0-2.

        Exclusion Criteria:

          -  CTCL with histologic evidence of folliculotropic variant or large cell transformed
             CTCL.

          -  Severe pruritus requiring systemic or topical treatment.

          -  Palpable lymph node ≥1.5 cm in diameter (unless the lymph node has been biopsied and
             has been designated as Stage IA-IIA disease).

          -  Coexistent second malignancy or history of prior solid organ malignancy within
             previous 5 years (excluding basal or squamous cell carcinoma of the skin, in situ
             carcinoma of the cervix (CIN 3), papillary or follicular thyroid cancer that has been
             treated curatively, or prostate cancer that has been treated curatively).

          -  Any prior history of a hematologic malignancy (other than CTCL).

          -  History of or current major renal, hepatic, gastrointestinal, pulmonary,
             cardiovascular, genito-urinary or hematological disease, CNS disorders, infectious
             disease or coagulation disorders as determined by the Investigator.

          -  Evidence of active Hepatitis B or C or HIV.

          -  Circulating atypical cells >5%
Clinical trial NCT00473551 (phase 1, status: terminated)
Conditions: leukemia, lymphoma, myeloma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00
Drugs: rituximab, cyclophosphamide, fludarabine, mesna, sirolimus
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, OS(=O)(=O)CCS, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Reason stopped: 
    terminated due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-70

          -  Confirmed diagnosis of follicular lymphoma, mantle cell lymphoma, chronic lymphocyte
             leukemia/small lymphocytic lymphoma or multiple myeloma. Patients must have had
             persistent or progressive disease despite initial chemotherapy. Patients must have
             achieved a partial or complete response to their most recent chemotherapy.

          -  Patients must have an human leukocyte antigen (HLA) matched (HLA-A, B, C DR or DQ)
             related donor who is seropositive against Epstein Barr virus and capable of donating
             peripheral blood mononuclear cells and peripheral blood progenitor cells.

          -  Patient must be HLA completely mismatched for HLA class I loci (A, B and C) with the
             3rd party stimulator cells. HLA-A (330301, 310102) HLA-B (5801,150101[62]) HLA-C
             (0302, 030301)

          -  Zubrod Performance Scale (PS) of 0 or 1

          -  Creatinine < 1.8 mg/dl

          -  Ejection fraction >/=40%

          -  Corrected Carbon Monoxide Diffusing Capacity (DLCO) >/=45% predicted

          -  Serum bilirubin </=1.5 mg/dl if not due to Gilbert's syndrome

        Exclusion Criteria:

          -  Uncontrolled infection

          -  HIV, hepatitis B surface antigen or hepatitis C seropositive

          -  serum glutamic-pyruvic transaminase (SGPT) > 200 IU/ml

          -  Pregnant or lactating women i.e., positive Beta human chorionic gonadotrophin (hCG)
             test in a woman with child bearing potential. Child bearing potential is defined as
             not post-menopausal for 12 months or no previous surgical sterilization.
Clinical trial NCT01294566 (phase 1, status: completed)
Conditions: gastroparesis
ICD codes: K31.84
Drugs: gsk1322888, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  AST, ALT, alkaline phosphatase and bilirubin < or =1.5xULN (isolated bilirubin
             >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

          -  Healthy as determined by a responsible and experienced physician

          -  Male or female between 18 (20 for Japanese) and 65 years of age inclusive

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception methods

          -  Body weight > or = 50 kg and BMI within the range 18.5 - 29.9 kg/m2 (inclusive).

          -  Capable of giving written informed consent

          -  Average QTc, QTcB or QTcF < 430 msec.

          -  For Japanese subjects Japanese ancestry defined as being born in Japan, having four
             ethnic Japanese grandparents, holding a Japanese passport or identity papers and being
             able to speak Japanese.

        Exclusion Criteria:

          -  Hepatitis B or Hepatitis C positive

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  A positive pre-study drug/alcohol screen.

          -  HIV positive

          -  History of regular alcohol consumption within 6 months of the study

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) prior to the first dose of study medication

          -  History of sensitivity to any of the study medications, or components thereof

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Pregnant females

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Subject is mentally or legally incapacitated.

          -  Regular use of tobacco- or nicotine-containing products within 6 months prior to
             screening.

          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
             to the first dose of study medication.

          -  Subjects will be screened such that those subjects exhibiting rapid gastric emptying
             rates (t½b < 75 min) will be excluded
Clinical trial NCT00374699 (phase 1/phase 2, status: completed)
Conditions: peripheral t-cell lymphomas, non-hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: velcade
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed PTCLs and NK/T cell lymphomas excluding anaplastic lymphoma
             kinase (ALK)-positive anaplastic large cell T-cell lymphomas (ALCL)

          -  Performance status (ECOG) ≤ 3

          -  Age ≤ 65

          -  At least one or more unidimensionally measurable lesion(s)

               -  ≥ 2 cm by conventional computed tomography (CT)

               -  ≥ 1 cm by spiral CT

               -  skin lesion (photographs should be taken)

               -  measurable lesion by physical examination

          -  Laboratory values

               -  Creatinine (Cr) < 1.5 mg% or creatinine clearance (Ccr) > 50 ml/min

               -  Transaminase < 3 X upper normal value

               -  Bilirubin < 2.0 mg/dl

               -  Absolute neutrophil count (ANC) > 1,500/ul

               -  Platelets > 75,000/ul

          -  Informed consent

          -  Ann Arbor stage III or IV

        Exclusion Criteria:

          -  Any other malignancies within the past 5 years except basal cell skin cancer or
             carcinoma in situ (CIS) of the cervix

          -  Serious comorbid diseases

          -  Pregnancy or breast feeding

        Any waiver of these inclusion and exclusion criteria must be approved by the investigator
        and the sponsor on a case-by-case basis prior to enrolling the subject. This must be
        documented by both the sponsor and the investigator. No subject will be allowed to enroll
        in this study more than once.
Clinical trial NCT01432106 (phase 1, status: withdrawn)
Conditions: hypertension, metabolic syndrome
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, E88.81
Drugs: aliskerin/valsartan and rampiril
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Reason stopped: 
    novartis terminated all projects involving aliskiren. findings of the dmc overseeing the
    altitude clinical trial found a higher incidence of adverse events.
  
Eligibility criteria:

        Inclusion Criteria:

          1. African American men or women 18 - 80 years of age.

          2. Appropriate therapy for high blood pressure consisting of no more than 2
             antihypertensives.

          3. Patients with at least one marker of Metabolic Syndrome as evidenced by:

               -  HDL cholesterol < 35mg/dl (men); < 45 mg/dl (women)

               -  Triglycerides > 200mg/dl

               -  Fasting Glucose >100mg/dl

               -  Waist Circumference: Men >40 inches (102cm); Women > 35 (88cm)

          4. Recent copy of EKG.

          5. Women able to become pregnant must use reliable contraception (e.g. hormonal
             contraception and double-barrier methods) throughout this study and for one week after
             the end of this study. Post-menopausal or surgically sterile women.

        Exclusion Criteria:

          1. Uncontrolled hypertension.

          2. Organ transplant.

          3. Hypersensitivity to any study medications

          4. Systolic pressure 170 or higher or Diastolic pressure 110 or higher.

          5. Cardiovascular events within last 6 months Stroke, Heart Attack, Stent, or
             Hospitalization for severe Heart Failure.

          6. Serum potassium greater than 5.0

          7. Heart block without a pacemaker, continuing arrhythmia or valvular heart disease.

          8. Blocked renal artery.

          9. Patients with severe renal impairment (creatinine 1.7 mg/dl for women and 2.0 mg/dl
             for men and or estimated GFR <30 mL/min) a history of dialysis, nephritic syndrome, or
             reno-vascular hypertension.

         10. Any condition that may alter medication absorption.

         11. Any condition that may place patient at higher risk from participating in study or
             will jeopardize the evaluation of efficacy or safety.

         12. Use of any investigational study medications within 30 days of enrollment

         13. Persons unwilling or unable to take regular medications or comply with study protocol.

         14. Pregnant or nursing (lactating) women, or women of childbearing potential (defined as
             all women physiologically capable of becoming pregnant) who do not use reliable
             methods of contraception: surgical sterilization, bilateral tubal ligation, hormonal
             contraception, implantable and oral) and double barrier methods if accepted by local
             regulatory authority and ethics committee. Reliable contraception should be maintained
             throughout the study and for 7 days after study drug discontinuation.
Clinical trial NCT00003060 (phase 1, status: terminated)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: busulfan, cyclophosphamide, cyclosporine, methotrexate
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Reason stopped: 
    lack of patient accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Biopsy proven relapsed malignant melanoma that has failed prior
        standard regimen for metastatic disease Must have HLA-matched or related bone marrow donor
        (5- or 6-antigen match) No history of CNS metastases

        PATIENT CHARACTERISTICS: Age: 16 to 44 Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: Not specified Hepatic: SGOT and SGPT less than 1.5 times
        upper limit of normal Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 1.5 mg/dL
        AND/OR Creatinine clearance greater than 75 mL/min Cardiovascular: No history of cardiac
        disease No symptomatic cardiac disease Ejection fraction greater than 50% Pulmonary: FEV1
        greater than 50% predicted (greater than 75% if received thoracic irradiation) DLCO greater
        than 50% predicted Other: Not pregnant Fertile women must use effective contraception HIV
        negative No active bacterial, fungal, or viral infection Hepatitis B negative

        PRIOR CONCURRENT THERAPY: At least 1 prior standard regimen for metastatic disease
Clinical trial NCT00724568 (phase 1/phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lenalidomide, bortezomib, dexamethasone, doxil
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria

          -  At least 18 years of age at the time of consent

          -  Measurable disease

          -  All necessary baseline studies completed

          -  LVEF (left ventricular ejection fraction) greater than or equal to 50 percent by MUGA
             (multigated acquisition scan) or ECHO (echocardiogram)

          -  Must be able to adhere to study visit schedule

        Exclusion

          -  Greater than or equal to grade 2 peripheral neuropathy on clinical examination within
             14 days of enrollment

          -  Renal insufficiency

          -  Evidence of mucosal or internal bleeding and/ or platelet refractory.

          -  Absolute neutrophil count less than 1000 cells/mm^2 within 14 days of enrollment.

          -  Acceptable labs

          -  Concomitant medications that include corticosteroids

          -  Myocardial infarction within 6 months prior to enrollment, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias

          -  Clinically relevant active infection or serious medical condition that places the
             subject at unacceptable risk

          -  Any condition, including laboratory values that places the subject at an unacceptable
             risk

          -  Another malignancy within 3 years of enrollment, with the exception of the complete
             resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ
             malignancy, or low risk prostate cancer after curative therapy

          -  Hypersensitivity to bortezomib, boron, or mannitol or any of the components of DOXIL

          -  Female subject that is pregnant or breastfeeding.

          -  Can not have received any other investigational drugs within 14 days of enrollment

          -  Serious medical or psychiatric illness

          -  Uncontrolled diabetes mellitus

          -  Hypersensitivity to acyclovir or similar antiviral drug

          -  POEMS (plasma cell dyscrasia with polyneuropathy)

          -  Known HIV

          -  Known hepatitis B or C

          -  Known intolerance to steroid therapy

          -  Known hypersensitivity to required prophylactic mediations
Clinical trial NCT00297089 (phase 1/phase 2, status: completed)
Conditions: lung cancer, nsclc, non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: abt-751, pemetrexed, placebo
SMILES: COC1=CC=C(C=C1)S(=O)(=O)NC1=C(NC2=CC=C(O)C=C2)N=CC=C1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically documented NSCLC

          -  Locally advanced (Stage III) or metastatic (Stage IV) NSCLC

          -  Only one prior anti-tumor treatment regimen in the non-curative setting (i.e.,
             2nd-line therapy)

          -  Only one prior anti-tumor treatment regimen in the curative setting

          -  Progressive disease following the previous anti-tumor treatment regimen

          -  Measurable disease by RECIST criteria

          -  Brain metastasis must be stable and well-controlled

          -  ECOG performance score 0-2

          -  All anti-tumor therapy discontinued at least 3 weeks prior to study entry

          -  All adverse events from prior treatment are resolved or stable

          -  Adequate hematologic, renal, and hepatic function

          -  Females must not be pregnant

          -  Willing to take adequate measures to prevent pregnancy

          -  Life expectancy of at least 3 months

          -  Able to complete the Quality of Life questionnaire

          -  Voluntarily signed informed consent

        Exclusion Criteria:

          -  Greater than Grade 1 neurological findings

          -  Allergy to sulfa medications

          -  Previous treatment with ABT-751 or pemetrexed

          -  Receipt of more than one investigational agent for NSCLC

          -  Significant weight loss (>10%) within 6 weeks of study entry

          -  Glucose-6-phosphate dehydrogenase deficiency or porphyria

          -  Significant systemic disease that would adversely affect participation

          -  Class 3-4 New York Heart Association classification status

          -  Other cancers except in situ carcinoma of the cervix, basal or squamous cell skin
             cancer, or any other cancer considered adequately treated and cured by the
             investigator
Clinical trial NCT00258258 (phase 1, status: terminated)
Conditions: multiple myeloma and plasma cell neoplasm
ICD codes: C96.20, C96.29, D47.09
Drugs: paricalcitol, zoledronic acid
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Reason stopped: 
    withdrawn due to low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of relapsed or refractory multiple myeloma (MM) or other plasma cell
             disorder (PCD)

               -  At least one previous treatment for MM or PCD required

        PATIENT CHARACTERISTICS:

        Performance status

          -  ECOG 0-2 OR

          -  Karnofsky 60-100%

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Calcium ≤ 10.5 mg/dL

          -  No renal stone formation within the past 5 years for patients who have had curative
             therapy for a condition associated with the risk of stones (e.g., hyperparathyroidism,
             bladder dysfunction, obstructive uropathy) OR had a single episode of confirmed
             urolithiasis

          -  No calculi in urinary tract confirmed by renal ultrasonography, kidney, ureter, and
             bladder (KUB) x-ray, or other imaging modality

        Cardiovascular

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No uncontrolled cardiac arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during study and for 3 months after
             study completion

          -  No osteonecrosis of the jaw

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biological composition of calcitriol, paricalcitol, or zoledronate

          -  No uncontrolled intercurrent illness that would preclude study compliance

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that may preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy

        Endocrine

          -  More than 4 weeks since prior high-dose steroids

        Other

          -  No other concurrent investigational agents or therapies for multiple myeloma or plasma
             cell disorders

          -  No concurrent digoxin